Stifel has initiated coverage of Cytokinetics (CYTK) with a buy rating, citing its drug aficamten, valuation and upcoming ...

Stifel analyst Chris O’Cull upgraded Portillo’s (PTLO) to Buy from Hold with a price target of $16, up from $13. The firm previously downgraded ...

Stifel Nicolaus analyst Nathan Jones maintained a Buy rating on Veralto Corporation (VLTO – Research Report) on January 24 and set a price ...

According to Stifel, the Meta partnership positions EssilorLuxottica at the forefront of the smart glasses revolution. The ...

Canadian investment dealer Eight Capital Corp. is winding down and many of its top staff are headed to Stifel Financial Corp.

Stifel analyst Brian Brophy raised the firm’s price target on Quanta Services (PWR) to $388 from $374 and keeps a Buy rating ...

After a painful crash early this season, Mikaela Shiffrin announced her return to the racecourse before the end of January.

Stifel lowered the firm’s price target on Fastenal (FAST) to $82 from $86 and keeps a Hold rating on the shares. Despite the ...

Thursday, January 23, 2025, marks the release of a new report by Stifel analysts on the US transport sector. The report outlines a cautious perspective on the industry's future, noting that while 2024 ...

Stifel analysts reiterated their Hold rating on Texas Instruments stock (NASDAQ:TXN) with a steady price target of $200.00.

Cytokinetics receives a Buy rating from Stifel, with a promising outlook for aficamten in the $3 billion U.S. oHCM market, ...

Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the ...